A comprehensive investigation of histotype-specific microRNA and their variants in Stage I epithelial ovarian cancers.
biomarker
histotype
miRNA
ovarian cancer
sequencing
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
revised:
23
11
2022
received:
26
09
2022
accepted:
30
11
2022
pubmed:
22
12
2022
medline:
9
3
2023
entrez:
21
12
2022
Statut:
ppublish
Résumé
isomiRs, the sequence-variants of microRNA, are known to be tissue and cell type specific but their physiological role is largely unknown. In our study, we explored for the first time the expression of isomiRs across different Stage I epithelial ovarian cancer (EOC) histological subtypes, in order to shed new light on their biological role in tumor growth and progression. In a multicentric retrospective cohort of tumor biopsies (n = 215) we sequenced small RNAs finding 971 expressed miRNAs, 64% of which are isomiRs. Among them, 42 isomiRs showed a clear histotype specific pattern, confirming our previously identified miRNA markers (miR192/194 and miR30a-3p/5p for mucinous and clear cell subtypes, respectively) and uncovering new biomarkers for all the five subtypes. Using integrative models, we found that the 38% of these miRNA expression alterations is the result of copy number variations while the 17% of differential transcriptional activities. Our work represents the first attempt to characterize isomiRs expression in Stage I EOC within and across subtypes and to contextualize their alterations in the framework of the large genomic heterogeneity of this tumor.
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1989-2001Informations de copyright
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer Oxf Engl 1990. 2013;49(6):1374-1403. doi:10.1016/j.ejca.2012.12.027
Leskela S, Romero I, Cristobal E, et al. The frequency and prognostic significance of the histologic type in early-stage ovarian carcinoma: a reclassification study by the Spanish Group for Ovarian Cancer Research (GEICO). Am J Surg Pathol. 2020;44(2):149-161. doi:10.1097/PAS.0000000000001365
Calura E, Fruscio R, Paracchini L. miRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. Clin Cancer Res. 2013;19(15):4114-4123. doi:10.1158/1078-0432.CCR-13-0360
Marchini S, Cavalieri D, Fruscio R, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 2011;12(3):273-285. doi:10.1016/S1470-2045(11)70012-2
Martini P, Paracchini L, Caratti G. lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study. Clin Cancer Res J Am Assoc Cancer Res. 2017;23(9):2356-2366. doi:10.1158/1078-0432.CCR-16-1402
Calura E, Martini P, Sales G. Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles. Nucleic Acids Res. 2014;42(11):e96. doi:10.1093/nar/gku354
Calura E, Paracchini L, Fruscio R. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment. Ann Oncol J Eur Soc Med Oncol. 2016;27(8):1511-1519. doi:10.1093/annonc/mdw210
Pesenti C, Beltrame L, Velle A, et al. Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis. Eur J Cancer Oxf Engl. 1990;2022(171):85-95. doi:10.1016/j.ejca.2022.05.005
Michlewski G, Cáceres JF. Post-transcriptional control of miRNA biogenesis. RNA. 2019;25(1):1-16. doi:10.1261/rna.068692.118
Zhang H, Su YL, Yu H, Qian BY. Meta-analysis of the association between Mir-196a-2 polymorphism and cancer susceptibility. Cancer Biol Med. 2012;9(1):63-72. doi:10.3969/j.issn.2095-3941.2012.01.012
Ghanbari M, Sedaghat S, Looper HWJ. The association of common polymorphisms in miR-196a2 with waist to hip ratio and miR-1908 with serum lipid and glucose: association of miRNA-SNPs with cardiometabolic traits. Obesity. 2015;23(2):495-503. doi:10.1002/oby.20975
Carter H, Marty R, Hofree M. Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov. 2017;7(4):410-423. doi:10.1158/2159-8290.CD-16-1045
Chacon-Cortes D, Smith RA, Haupt LM, Lea RA, Youl PH, Griffiths LR. Genetic association analysis of miRNA SNPs implicates MIR145 in breast cancer susceptibility. BMC Med Genet. 2015;16(1):107. doi:10.1186/s12881-015-0248-0
Wu H, Ye C, Ramirez D, Manjunath N. Alternative processing of primary microRNA transcripts by Drosha generates 5′ end variation of mature microRNA. PLoS One. 2009;4(10):e7566. doi:10.1371/journal.pone.0007566
Kim B, Jeong K, Kim VN. Genome-wide mapping of DROSHA cleavage sites on primary microRNAs and noncanonical substrates. Mol Cell. 2017;66(2):258-269. doi:10.1016/j.molcel.2017.03.013
Roden C, Gaillard J, Kanoria S. Novel determinants of mammalian primary microRNA processing revealed by systematic evaluation of hairpin-containing transcripts and human genetic variation. Genome Res. 2017;27(3):374-384. doi:10.1101/gr.208900.116
Kwon SC, Baek SC, Choi YG. Molecular basis for the single-nucleotide precision of primary microRNA processing. Mol Cell. 2019;73(3):505-518. doi:10.1016/j.molcel.2018.11.005
Gu S, Jin L, Zhang Y. The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing In vivo. Cell. 2012;151(4):900-911. doi:10.1016/j.cell.2012.09.042
Zhu L, Kandasamy SK, Fukunaga R. Dicer partner protein tunes the length of miRNAs using base-mismatch in the pre-miRNA stem. Nucleic Acids Res. 2018;46(7):3726-3741. doi:10.1093/nar/gky043
Jones MR, Quinton LJ, Blahna MT. Zcchc11-dependent uridylation of microRNA directs cytokine expression. Nat Cell Biol. 2009;11(9):1157-1163. doi:10.1038/ncb1931
Yamane D, Selitsky SR, Shimakami T, et al. Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3′ variants. Nucleic Acids Res. 2017;45:4743-4755. doi:10.1093/nar/gkw1332
Yu F, Pillman KA, Neilsen CT. Naturally existing isoforms of miR-222 have distinct functions. Nucleic Acids Res. 2017;45(19):11371-11385. doi:10.1093/nar/gkx788
Khudayberdiev SA, Zampa F, Rajman M, Schratt G. A comprehensive characterization of the nuclear microRNA repertoire of post-mitotic neurons. Front Mol Neurosci. 2013;6:6. doi:10.3389/fnmol.2013.00043
Koppers-Lalic D, Hackenberg M, Bijnsdorp I. Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. Cell Rep. 2014;8(6):1649-1658. doi:10.1016/j.celrep.2014.08.027
Katoh T, Sakaguchi Y, Miyauchi K. Selective stabilization of mammalian microRNAs by 3′ adenylation mediated by the cytoplasmic poly(a) polymerase GLD-2. Genes Dev. 2009;23(4):433-438. doi:10.1101/gad.1761509
Burns DM, D'Ambrogio A, Nottrott S, Richter JD. CPEB and two poly(a) polymerases control miR-122 stability and p53 mRNA translation. Nature. 2011;473(7345):105-108. doi:10.1038/nature09908
Calura E, Ciciani M, Sambugaro A. Transcriptional characterization of stage I epithelial ovarian cancer: a multicentric study. Cell. 2019;8(12):1554. doi:10.3390/cells8121554
Kurman RJ. International Agency for Research on Cancer. 4th ed. Lyon, France: World Health Organization; 2014.
Didion JP, Martin M, Collins FS. Atropos: specific, sensitive, and speedy trimming of sequencing reads. PeerJ. 2017;5:e3720. doi:10.7717/peerj.3720
Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25. doi:10.1186/gb-2009-10-3-r25
Desvignes T, Loher P, Eilbeck K, et al. Unification of miRNA and isomiR research: the mirGFF3 format and the mirtop API. Bioinformatics. 2020;36(3):698-703. doi:10.1093/bioinformatics/btz675
Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155-D162. doi:10.1093/nar/gky1141
Lorena Pantano and Georgia Escaramis. isomiRs: analyze isomiRs and miRNAs from small RNA-seq. R package version 1.18.1; 2021.
Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol. 2014;32(9):896-902. doi:10.1038/nbt.2931
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-140. doi:10.1093/bioinformatics/btp616
Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278-1284. doi:10.1038/ng2135
Wu T, Hu E, Xu S. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2(3):100141. doi:10.1016/j.xinn.2021.100141
Poell JB, Mendeville M, Sie D, Brink A, Brakenhoff RH, Ylstra B. ACE: absolute copy number estimation from low-coverage whole-genome sequencing data. Bioinformatics. 2019;35(16):2847-2849. doi:10.1093/bioinformatics/bty1055
Tong Z, Cui Q, Wang J, Zhou Y. TransmiR v2.0: an updated transcription factor-microRNA regulation database. Nucleic Acids Res. 2019;47(D1):D253-D258. doi:10.1093/nar/gky1023
Ahn G, Folkins AK, McKenney JK, Longacre TA. Low-grade serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion. Am J Surg Pathol. 2016;40(9):1165-1176. doi:10.1097/PAS.0000000000000693
Vang R, Shih IM, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 2013;62(1):44-58. doi:10.1111/his.12046
Lõhmussaar K, Kopper O, Korving J, et al. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. Nat Commun. 2020;11(1):2660. doi:10.1038/s41467-020-16432-0
Babaier A, Mal H, Alselwi W, Ghatage P. Low-grade serous carcinoma of the ovary: the current status. Diagnostics. 2022;12(2):458. doi:10.3390/diagnostics12020458
Kandimalla R, Wang W, Yu F, et al. OCaMIR-A noninvasive, diagnostic signature for early-stage ovarian cancer: a multi-cohort retrospective and prospective study. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(15):4277-4286. doi:10.1158/1078-0432.CCR-21-0267
Qi X, Yu C, Wang Y, Lin Y, Shen B. Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer. Clin Transl Med. 2019;8(1):28. doi:10.1186/s40169-019-0245-6
Benvenuto G, Todeschini P, Paracchini L, et al. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. Int J Cancer. 2020;147(2):565-574. doi:10.1002/ijc.32935
Ferreira P, Roela RA, Lopez RVM, Del Pilar E-DM. The prognostic role of microRNA in epithelial ovarian cancer: a systematic review of literature with an overall survival meta-analysis. Oncotarget. 2020;11(12):1085-1095. doi:10.18632/oncotarget.27246
Jacques C, Tesfaye R, Lavaud M. Implication of the p53-related miR-34c, -125b, and -203 in the osteoblastic differentiation and the malignant transformation of bone sarcomas. Cell. 2020;9(4):810. doi:10.3390/cells9040810
Achari C, Winslow S, Ceder Y, Larsson C. Expression of miR-34c induces G2/M cell cycle arrest in breast cancer cells. BMC Cancer. 2014;14(1):538. doi:10.1186/1471-2407-14-538
Hagman Z, Larne O, Edsjö A, et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer. 2010;127(12):2768-2776. doi:10.1002/ijc.25269
Wu Z, Wu Y, Tian Y. Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells. Oncol Lett. 2013;6(5):1447-1452. doi:10.3892/ol.2013.1579
Liu F, Wang X, Li J. miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer. Cell Prolif. 2015;48(5):582-592. doi:10.1111/cpr.12201
Yan M, Yang X, Shen R, et al. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer. Cell Death Dis. 2018;9(11):1123. doi:10.1038/s41419-018-1093-9
Wang Y, Zhao S, Zhu L, Zhang Q, Ren Y. MiR-19a negatively regulated the expression of PTEN and promoted the growth of ovarian cancer cells. Gene. 2018;670:166-173. doi:10.1016/j.gene.2018.05.063
Chen X, Yang F, Zhang T. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma. J Exp Clin Cancer Res. 2019;38(1):99. doi:10.1186/s13046-019-1078-2